Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the ona domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/risezcom/public_html/cord-blood.org.uk/wp-includes/functions.php on line 6131
Study finds new way to manage diabetes during pregnancy - Cord Blood

Cord Blood

and Stem Cell Banking

Study finds new way to manage diabetes during pregnancy

Woman taking pill

Managing diabetes during pregnancy just got easier, thanks to a recent study conducted in Ireland. Gestational diabetes, a type of diabetes that occurs during pregnancy, can have negative effects on both mothers and babies. But the study, carried out at the University of Galway, has found a potential solution – a medication called metformin.

What is gestational diabetes?

Gestational diabetes is a condition where pregnant women have high blood sugar levels. It affects nearly three million pregnant women worldwide each year. This condition can be risky for both the mother and the baby.

The study

The trial involved 535 pregnant women, with half receiving metformin and the other half receiving a placebo. The results were impressive. Women who took metformin were 25% less likely to need insulin, and if they did need insulin, it was started later in the pregnancy. Additionally, the study found that women in the metformin group had lower sugar levels both before and after meals.

Positive outcomes

The study revealed some positive outcomes for both mothers and babies. The women who took metformin had infants who weighed, on average, 113g (0.25 pounds) less at birth. These babies were also less likely to be classified as large at birth or weigh over 4kg (8lbs 8oz). While the babies were slightly shorter, no other significant differences in measurements were found.

Safety concerns

One concern about metformin was whether it would lead to preterm birth or affect infant size. However, the study found no increase in preterm birth among the women who took metformin. There were also no differences in adverse neonatal outcomes, such as the need for intensive care treatment or respiratory support.

Better management approach

Traditionally, gestational diabetes has been managed through diet and exercise. If blood sugar levels remained high, insulin would be introduced. But insulin use can come with challenges, such as low sugar levels for both mother and baby, excess weight gain for mothers, and higher rates of caesarean births. Metformin can offer an alternative treatment option that is effective and safe.

Conclusion

This study is a significant step forward in managing gestational diabetes during pregnancy. Metformin has proven to be an effective alternative to insulin, with fewer risks for both mothers and babies. By using metformin, women with gestational diabetes can reduce the need for insulin and have better control over their blood sugar levels. This new approach can improve pregnancy outcomes and reduce the risk of complications for both mother and baby.